A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer

Summary

This is a multicenter, double-blind, placebo-controlled, randomized, phase II study to investigate the efficacy and safety of Atezolizumab with or without Tiragolumab as consolidation therapy in participants with limited stage small cell lung cancer who have not progressed during/after chemoradiotherapy.

Timeline

Start

2021-12-01

Primary completion

2023-07-25

Completion

2023-07-25

Outcome

Outcome not reported

Stopped: “The sponsor's decision was based on the negative results of SKYSCRAPER-02.”

Drugs

Indications